Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Florence K. Kadjo"'
Autor:
Julie K. Sackou, Marie L. Tiadé, Annita A. Hounsa, Simone K. Malik, Madikiny Coulibaly, Angèle A. Desquith, Florence K. Kadjo, Serge A. Agoua, Serge Oga, Luc K. Kouadio
Publikováno v:
Journal of Public Health in Africa, Vol 10, Iss 2 (2020)
Hypertension affects more than a quarter of the world adult population, with ruralurban disparities. In Côte d’Ivoire, the prevalence was 21.7% in 2005. The aim of this study was to determine factors associated with hypertension in a peri-urban co
Externí odkaz:
https://doaj.org/article/17515091ea654554a1047f91f3343593
Autor:
Marie Laure Tiadé, Serge A. Agoua, Madikiny Coulibaly, Julie Sackou, Luc Kouakou Kouadio, Angèle A. Desquith, Annita A. Hounsa, Simone Malik, Florence K. Kadjo, Serge Oga
Publikováno v:
Journal of Public Health in Africa
Journal of Public Health in Africa, Vol 10, Iss 2 (2020)
Journal of Public Health in Africa, Vol 10, Iss 2 (2020)
Hypertension affects more than a quarter of the world adult population, with ruralurban disparities. In Côte d’Ivoire, the prevalence was 21.7% in 2005. The aim of this study was to determine factors associated with hypertension in a peri-urban co
Autor:
Landry T N'guessan, Louis K. Penali, Moïse K San, Andre Toure Offianan, Aristide Ma Coulibaly, Florence K Kadjo, Aristide A Ako, Serge B Assi
Publikováno v:
Open Access Journal of Clinical Trials. :67
Correspondence: Andre T Offianan Malariology Department, Institut Pasteur de Cote d’Ivoire, PO Box 490, Abidjan 01, Cote d’Ivoire Tel +225 22 44 84 25 Fax +225 22 48 53 05 Email andre_offianan@yahoo.fr Background: The emergence of artemisinin res
Autor:
Issiaka Bassinka, Serge B. Assi, Marie F Ehouman, Offianan Andre Toure, Aristide Berenger Ako, Florence K Kadjo, Laeticia A Gnamien, Gbessi E Adji, Baba Coulibaly, Sylvain Beourou, Adama Soumahoro, M'Lanhoro A A Coulibaly, Tiacoh L N'Guessan, Marie J Brou, Mea A Tano
Publikováno v:
Malaria Journal
Background Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments f